References
- Weintraub D, Comella CL, Horn S. Parkinson’s disease – part 1: pathophysiology, symptoms, burden, diagnosis and assessment. Am. J. Manag. Care14(2 Suppl.), S40–S48 (2008).
- Shapira A. Future directions in the treatment of Parkinson’s disease. Mov. Disord.22, S385–S391 (2007).
- Marras C, Lang A. Invited article: changing concepts in Parkinson disease: moving beyond the decade of the brain. Neurology70, 1996–2003 (2008).
- Wu SS, Frucht SJ. Treatment of Parkinson’s disease: what’s on the horizon? CNS Drugs19, 723–743 (2005).
- Yamamoto M, Schapira AH. Dopamine agonists in Parkinson’s disease. Expert Rev. Neurother.8, 671–677 (2008).
- Sudo J, Iwase H, Terui J et al. Transdermal absorption of L-dopa from hydrogel in rats. Eur. J. Pharm. Sci.7, 67–71 (1998).
- Nyholm D, Nilsson RA, Dizdar N et al. Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease. Neurology64, 182–183 (2005).
- Pahaw R, Stacy MA, Factor SA et al.; EASE-PD Adjunct Study Investigators. Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease. Neurology68, 1108–1115 (2007).
- Glennon JC, Van Scharrenburg G, Ronken E et al.In vitro characterization of SLV308 (7-[4-methyl-1-piperazinyl]-2[3H]-benzoxazolone, monohydrochloride): a novel partial dopamine D2 and D3 receptor agonist and serotonin 5-HT1Areceptor agonist. Synapse60, 599–608 (2006).
- Heinrich JN, Brennan J, Lai MH et al. Aplindore (DAB-452), a high affinity selective dopamine D2 receptor partial agonist. Eur. J. Pharmacol.552, 36–45 (2006).
- DA agonists – ergot derivatives: lisuride: management of Parkinson’s disease. Mov. Disord.17(Suppl.4), S74–S78 (2002).
- Woitalla D, Muller T, Benz S, Horowski R, PrzuntekH. Transdermal lisuride delivery in the treatment of Parkinson’s disease. J. Neural Transm. Suppl.68, 89–95 (2004).
- Bonifácio MJ, Palma PN, Almeida L, Soares-da-Silva P. Catechol-O-methyltransferase and its inhibitors in Parkinson’s disease. CNS Drug Rev.13, 352–379 (2007).
- Ferreira JJ, Almeida L, Cunha L et al. Effects of nebicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity, and motor fluctuations in patients with Parkinson disease. Clin. Neuropharmacol.31, 2–18 (2008).
- Fernandez HH, Chen JJ. Monoamine oxidase-B inhibition in the treatment of Parkinson’s disease. Pharmacotherapy27, 174S–185S (2007).
- Rascol O, Poewe W, Lees A et al. Tesofensine (NS 2330), a monoamine reuptake inhibitor, in patients with advanced Parkinson disease and motor fluctuations: the ADVANS Study. Arch. Neurol.65, 577–583 (2008).
- Schwarzschild MA, Agnati L, Fuxe K, Chen JF, Morelli M. Targeting adenosine A2A receptors in Parkinson’s disease. Trends Neurosci.29, 647–654 (2006).
- Stacy M, Silver D, Mendis T et al. A 12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson disease. Neurology70, 2233–2240 (2008).
- LeWitt PA, Guttman M, Tetrud JW et al. Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces “off” time in Parkinson’s disease: a double-blind, randomized, multicenter clinical trial (6002-US-005). Ann. Neurol.63, 295–302 (2008).
- Marino MJ, Valenti O, Conn PJ. Glutamate receptors and Parkinson’s disease: opportunities for intervention. Drugs Aging20, 377–397 (2003).
- Bonsi P, Cuomo D, Picconi B. Striatal metabotropic glutamate receptors as a target for pharmacotherapy in Parkinson’s disease. Amino Acids32, 189–195 (2007).
- Savola JM, Hill M, Engstrom M et al. Fipamezole (JP-1730) is a potent a2 adrenergic receptor antagonist that reduces levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson’s disease. Mov. Disord.18, 872–873 (2003).
- Murata M, Hasegawa K, Kanazawa I; The Japan Zonisamide on PD Study Group. Zonisamide improves motor function in Parkinson disease: a randomized, double-blind study. Neurology68, 45–50 (2007).
- Murata M. Novel therapeutic effects of the anti-convulsant, zonisamide, on Parkinson’s disease. Curr. Pharm. Des.10, 687–693 (2004).
- Asanuma M, Miyazaki I, Diaz-Corrales FJ, Miyoshi K, Ogawa N, Murata M. Preventing effects of a novel anti-parkinsonian agent zonisamide on dopamine quinone formation. Neurosci. Res.60, 106–113 (2008).
- LeWitt PA, Taylor DC. Protection against Parkinson’s disease progression: clinical experience. Neurotherapeutics5, 2210–2225 (2008).
- Ravina BM, Fagan SC, Hart RG et al. Neuroprotective agents for clinical trials in Parkinson’s disease: a systematic assessment. Neurology60, 1234–1240 (2003).
- NINDS NET-PD Investigators. A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease. Neurology66, 664–671 (2006).
- The NINDS NET-PD Investigators. A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease. Neurology68, 20–28 (2007).
- NINDS NET-PD Investigators. A pilot clinical trial of creatine and minocycline in early Parkinson disease: 18-month results. Clin. Neuropharmacol.31, 141–150 (2008).
- Storch A, Jost WH, Vieregge P et al.; German Coenzyme Q(10) Study Group. Randomized, double-blind, placebo-controlled trial on symptomatic effects of coenzyme Q(10) in Parkinson disease. Arch. Neurol.64, 938–944 (2007).
- Schneider JS, Roeltgen DP, Mancall EL, Chapas-Crilly J, Rothblat DS, Tatarian GT. Parkinson’s disease: improved function with GM1 ganglioside treatment in a randomized placebo-controlled study. Neurology50, 1630–1636 (1998).
- Crotty S, Fitzgerald P, Tuohy E et al. Neuroprotective effects of novel phosphatidylglycerol-based phospholipids in the 6-hydroxydopamine model of Parkinson’s disease. Eur. J. Neurosci.27, 294–300 (2008).
- Visanji NP, Orsi A, Johnston TH et al. PYM50028, a novel, orally active, nonpeptide neurotrophic factor inducer, prevents and reverses neuronal damage induced by MPP+ in mesencephalic neurons and by MPTP in a mouse model of Parkinson’s disease. FASEB J.22(7), 2488–2497 (2008).
- Liang LP, Huang J, Fulton R, Day BJ, Patel M. An orally active catalytic metalloporphyrin protects against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity in vivo.J. Neurosci.27, 4326–4333 (2007).
- Amer D, Irine GB, El-Agnaf O. Inhibitors of α-synuclein oligomerization and toxicity: a future therapeutic stategy for Parkinson’s disease and related disorders. Exp. Brain Res.173, 223–233 (2006).
- Li J, Zhu M, Rajamani S, Uversky VN, Fink AL. Rifampicin inhibits α-synuclein fibrillation and disaggregates fibrils. Chem. Biol.11, 1513–1521 (2004).
- Qureshi GA, Qureshi AA, Devrajani BR, Chippa MA, Syed SA. Is the deficiency of vitamin B12 related to oxidative stress and neurotoxicity in Parkinson’s patients? CNS Neurol. Disord. Drug Targets7, 20–27 (2008).
- Newmark HL, Newmark J. Vitamin D and Parkinson’s disease – a hypothesis. Mov. Disord.22, 461–468 (2007).
- Peterson AL, Nutt JG. Treatment of Parkinson’s disease with trophic factors. Neurotherapeutics5, 270–280 (2008).
- Lang AE, Gill S, Patel NK et al. Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann. Neurol.59, 459–466 (2006).
- Nutt JG, Burchiel KJ, Comella CL et al. Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. Neurology60, 69–73 (2003).
- Lindvall O, Wahlberg LU. Encapsulated cell biodelivery of GDNF: a novel clinical strategy for neuroprotection and neuroregeneration in Parkinson’s disease? Exp. Neurol.209, 82–88 (2008).
- Freed CR, Greene PE, Breeze RE et al. Transplantation of embryonic dopamine neurons for severe Parkinson’s disease. N. Engl. J. Med.344, 710–719 (2001).
- Olanow CW, Goetz CG, Kordower JH et al. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson’s disease. Ann. Neurol.54, 403–414 (2003).
- Astradsson A, Cooper O, Vinuela A, Isacson O. Recent advances in cell-based therapy for Parkinson disease. Neurosurg. Focus24(3–4), E6 (2008).
- Kaplitt MG, Feigin A, Tang C et al. Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson’s disease: an open label, Phase I trial. Lancet369, 2097–2105 (2007).
- Stover NP, Bakay RA, Subramanian T et al. Intrastriatal implantation of human retinal pigment epithelial cells attached to microcarriers in advanced Parkinson disease. Arch. Neurol.62, 1833–1837 (2005).
- Rossini PM, Rossi S. Transcranial magnetic stimulation: diagnostic, therapeutic, and research potential. Neurology68, 484–488 (2007).
- Tsuji S, Akamatsu N. Does transcranial magnetic stimulation improve the motor symptoms of Parkinson disease? J. Neurol.250(Suppl. 3), III47–III50 (2003).
- Fregni F, Simon DK, Wu A, Pascual-Leone A. Non-invasive brain stimulation for Parkinson’s disease: a systematic review and meta-analysis of the literature. J. Neurol. Neurosurg. Psychiatry76, 1614–1623 (2005).
- Lomarev MP, Kanchana S, Bara-Jimenez W, Iyer M, Wassermann EM, Hallett M. Placebo-controlled study of rTMS for the treatment of Parkinson’s disease. Mov. Disord.21, 325–331 (2006).
- Arle JE, Shils JL. Motor cortex stimulation for pain and movement disorders. Neurotherapeutics5, 37–49 (2008).
- Buter TC, van den Hout A, Matthews FE, Larsen JP, Brayne C, Aarsland D. Dementia and survival in Parkinson disease: a 12-year population study. Neurology70, 1017–1022 (2008).
- Merello M, Nouzeilles MI, Cammarota A, Leiguarda R. Effect of memantine (NMDA antagonist) on Parkinson’s disease: a double-blind crossover randomized study. Clin. Neuropharmacol.22, 273–276 (1999).
- Tzavara ET, Bymaster FP, Overshiner CD et al. Procholinergic and memory enhancing properties of the selective norepinephrine uptake inhibitor atomoxetine. Mol. Psychiatry11, 187–195 (2006).
- Parkinson Study Group. Low-dose clozapine for the treatment of drug induced psychosis in Parkinson’s disease. N. Engl. J. Med.340, 757–763 (1999).
- Miyasaki JM, Shannon K, Voon V et al. Practice parameter: evaluation and treatment of depression, psychosis and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology66, 996–1002 (2006).
- Gardell LR, Vanover KE, Pounds L et al. ACP-103 , a 5-hydroxytryptamine 2A receptor inverse agonist, improves the antipsychotic efficacy and side-effect profile of haloperidol and risperidone in experimental models. J. Pharmacol. Exp. Ther.332, 862–870 (2007).
- Voon V, Fox SH. Medication-related impulse control and repetitive behaviors in Parkinson disease. Arch. Neurol.64, 1089–1096 (2007).
- De Witte P, Littleton J, Parot P, Koob G. Neuroprotective and abstinence-promoting effects of acamprosate: elucidating the mechanism of action. CNS Drugs19, 517–537 (2005).
- Cowen MS, Adams C, Kraehenbuehl T, Vengeliene V, Lawrence AJ. The acute anti-craving effect of acamprosate in alcohol-preferring rats is associated with modulation of the mesolimbic dopamine system. Addict. Biol.10, 233–242 (2005).
- Mathias CJ. L-dihydroxyphenylserine (Droxidopa) in the treatment of orthostatic hypotension: the European experience. Clin. Auton. Res.18(Suppl. 1), 25–29 (2008).
Patent
- FIDIA SPA: US6620792 (1994).
Websites
- Parkinson Pipeline Project www.pdpipeline.org (Accessed 20 June 2008)
- Vernalis www.vernalis.com/ver/rdc2/neurology/v1512 (Accessed 19 June 2008)
- Vernalis Development; Cita NeuroPharmaceuticals; Kendle International. PK, PD and safety of multiple doses of v1512 tablets in PD patients compared to standard levodopa/carbidopa oral tablets. National Library of Medicine, Bethesda, MD, USA (2000). NLM Identifier: NCT 00491998 http://clinicaltrials.gov/show/ NCT00491998 (Accessed 19 June 2008)
- NeuroDerm www.neuroderm.co.il/overview.html (Accessed 20 June 2008)
- Solvay Pharmaceuticals www.solvaypharmaceuticals.com/Products/group/product/0,,30641–30642-0,00.htm (Accessed 20 June 2008)
- Solvay’s Duodopa intestinal gel gets FDA fast track status for Parkinson’s. AFX News Limited www.forbes.com/markets/feeds/afx/2008/02/19/afx4667956.html (Accessed 30 June 2008)
- XenoPort www.xenoport.com/product/xp21279.htm (Accessed June 20 2008)
- Solvay Pharmaceuticals. SLV308 for treatment of patients with early Parkinson’s disease. National Library of Medicine, Bethesda, MD, USA (2000). NLM Identifier: NCT00269516 http://clinicaltrials.gov/show/ NCT00269516 (Accessed 22 June 2008)
- Neurogen Corporation. The effects of aplindore on the treatment of signs and symptoms of Parkinson’s disease. National Library of Medicine, Bethesda, MD, USA (2000). NLM Identifier: NCT00623324 http://clinicaltrials.gov/show/ NCT00623324 (Accessed 22 June 2008)
- Axxonis Pharma AG Berlin submits a European marketing authorisation application for Nenad® (lisuride) transdermal patch and subcutaneous infusion www.axxonis.com/news/news_docs/de/news/AxxonisPharma_EMEA_Presse_engl_040608%20.pdf (Accessed 20 June 2008)
- National Institute of Neurological Disorders and Stroke. Lisuride patch to treat Parkinsons’s disease. National Library of Medicine, Bethesda, MD, USA (2000). NLM Identifier: NCT00089622 http://clinicaltrials.gov/show/ NCT00089622 (Accessed 20 June 2008)
- Vectura announces successful outcome of second Phase II clinical study from Parkinson’s disease programme www.vectura.co.uk/vec/news/releases/2007/2007-2010-31 (Accessed 22 June 2008)
- Britannia Pharmaceuticals Ltd. Apomorphine nasal powder in the treatment of Parkinson’s disease “off” periods. National Library of Medicine, Bethesda, MD, USA (2000). NLM Identifier: NCT00346827 http://clinicaltrials.gov/show/ NCT00346827 (Accessed 22 June 2008)
- EMD Serono. A Phase III, double-blind, placebo-controlled randomised trial to determine the efficacy and safety of a low and high dose of safinamide, as add-on therapy, in subjects with early idiopathic Parkinson’s disease (MOTION). National Library of Medicine, Bethesda, MD, USA (2000). NLM Identifier: NCT00605683 http://clinicaltrials.gov/show/ NCT00605683 (Accessed 23 June 2008)
- NeuroSearch continues the development of tesofensine (NS2330) and Boehringer Ingelheim returns all rights to NeuroSearch. January 25 (2006). www.neurosearch.com/Default.aspx?ID=1778&M=News&PID=10090&NewsID=15080 (Accessed 23 June 2008)
- NeuroSearch www.neurosearch.com/Default.aspx?ID=754 (Accessed 22 June 2008)
- Kyowa releases results to Phase III clinical studies of an anti-Parkinson’s disease drug istradefylline (KW-6002) Conducted Overseas. 7 March, (2006) www.kyowa-kpi.com/PressRelease-03-07-06.html (Accessed 24 June 2008)
- Schering-Plough. Dyskinesia in Parkinson’s disease (Study P04501AM30). National Library of Medicine, Bethesda, MD, USA (2000). NLM Identifier: NCT00406029 http://clinicaltrials.gov/show/ NCT00406029 (Accessed 25 June 2008)
- Biogen Idec. Dose-finding safety study of BIIB014 in combination With levodopa in moderate to late stage Parkinson’s disease. National Library of Medicine, Bethesda, MD, USA (2000). NLM Identifier: NCT00438607 http://clinicaltrials.gov/show/ NCT00438607 (Accessed 25 June 2008)
- Biogen Idec. Dose-finding safety study of BIIB014 in early-stage Parkinson’s disease (MOBILE). National Library of Medicine, Bethesda, MD, USA (2000) NLM Identifier: NCT00442780 http://clinicaltrials.gov/show/ NCT00442780 (Accessed 25 June 2008)
- Novel agent for treatment of Parkinson’s disease in clinical development www.lundbeck.com/investor/releases/ReleaseDetails/Release_1168032_EN.asp (Accessed 25 June 2008)
- Eisai Limited. Evaluation of the long-term safety, tolerability, and efficacy of perampanel (E2007) as an adjunctive therapy in levodopa treated Parkinson’s disease subjects with motor fluctuations. National Library of Medicine, Bethesda, MD, USA (2000) NLM Identifier: NCT00505622 http://clinicaltrials.gov/show/ NCT00505622 (Accessed 25 June 2008)
- Status Of the E2007 (perampanel) development program. Medical News Today. 12 April (2008) www.medicalnewstoday.com/articles/103759.php (Accessed 25 June 2008)
- National Institute of Neurological Disorders and Stroke (NINDS). Talampanel to treat Parkinson’s disease. National Library of Medicine, Bethesda, MD, USA (2000). NLM Identifier: NCT00108667 http://clinicaltrials.gov/show/ NCT00108667 (Accessed 25 June 2008)
- Teva Pharmaceuticals Ltd. www.tevapharm.com/research/products_ni.asp (Accessed 30 June 2008)
- Addex Pharmaceuticals www.addexpharma.com/pipeline (Accessed 23 June 2008)
- Faust Pharmaceuticals www.faustpharma.com/html/Development/Projects/FP0011 (Accessed 25 June 2008)
- Juvantia Pharma Ltd. Safety and efficacy study of fipamezole in treatment of motor dysfunctions in Parkinson’s disease. National Library of Medicine, Bethesda, MD, USA (2000). NLM Identifier: NCT00559871 http://clinicaltrials.gov/show/ NCT00559871(Accessed 23 June 2008)
- Profile of major products under development. Dainippon Sumitomo Pharma Co., Ltd. 9 May, 2008 www.ds-pharma.co.jp/english/rd/pdf/prof_20080509e.pdf (Accessed 29 June 2008)
- National Institute of Neurological Disorders and Stroke (NINDS). NET-PD LS-1 creatine in Parkinson’s disease. National Library of Medicine, Bethesda, MD, USA (2000). NLM Identifier: NCT00449865 http://clinicaltrials.gov/show/ NCT00449865 (Accessed 28 June 2008)
- Fidia www.fidiapharma.com/files/index.cfm?id_rst=102 (Accessed 28 June 2008)
- Thomas Jefferson University, National Institute of Neurological Disorders and Stroke (NINDS). GM1 ganglioside effects on Parkinson’s disease. National Library of Medicine, Bethesda, MD, USA (2000). NLM Identifier: NCT00037830 http://clinicaltrials.gov/show/ NCT00037830 (Accessed 28 June 2008)
- Vasogen www.vasogen.com/sec/vp015 (Accessed June 28 2008)
- Phytopharm plc interim results www.phytopharm.co.uk/news/newsreleases/?id=8391 (Accessed 29 June 2008)
- Aeolus Pharmaceuticals www.aeoluspharma.com/parkinsons.php (Accessed 28 June 2008)
- Harby K. Redirected therapies: repurposing compounds for use against neurodegenerative diseases. New York Academy of Sciences E-Briefings. 5 July 2007 www.nyas.org/ebriefreps/main.asp?intEBriefID=649 (Accessed 9 July 2008)
- Link Medicine www.linkmedicine.com (Accessed 9 July 2008)
- Emory University, National Institute of Health (NIH). Vitamin B12 status and response to vitamin B12 supplementation in patients with Parkinson’s disease. National Library of Medicine, Bethesda, MD, USA (2000). NLM Identifier: NCT00208611 http://clinicaltrials.gov/show/ NCT00208611 (Accessed 29 June 2008)
- Emory University. Clinical effects of vitamin D repletion in patients with Parkinson’s disease (VIDIP PILOT). National Library of Medicine, Bethesda, MD, USA (2000). NLM Identifier: NCT00571285 http://clinicaltrials.gov/show/ NCT00571285 (Accessed 29 June 2008)
- Ceregene. Double-blind, multicenter, sham surgery controlled study of CERE-120 for efficacy and safety in subjects with idiopathic Parkinson’s disease. National Library of Medicine, Bethesda, MD, USA (2000). NLM Identifier: NCT00400634 http://clinicaltrials.gov/show/ NCT00400634 (Accessed 25 June 2008)
- BrainStrom Cell Therapeutics www.brainstorm-cell.com (Accessed 27 June 2008)
- Neurologix, Inc. – Phase 2 Safety and efficacy study of AAV-GAD gene transfer into the subthalamic nucleus for Parkinson’s disease. National Library of Medicine, Bethesda, MD, USA (2000). NLM Identifier: NCT00643890 http://clinicaltrials.gov/show/ NCT00643890 (Accessed 1 July 2008)
- Oxford Biomedica www.oxfordbiomedica.co.uk/prosavin.htm (Accessed 25 June 2008)
- Oxford BioMedica. Phase I/II study of the safety, efficacy and dose evaluation of ProSavin for the treatment of bilateral idiopathic Parkinson’s disease. National Library of Medicine, Bethesda, MD, USA (2000). NLM Identifier: NCT00627588 http://clinicaltrials.gov/show/ NCT00627588 (Accessed 25 June 2008)
- Genzyme. A study of AAV-hAADC-2 in subjects with Parkinson’s disease. National Library of Medicine, Bethesda, MD, USA (2000). NLM Identifier: NCT00229736 http://clinicaltrials.gov/show/ NCT00229736 (Accessed 25 June 2008)
- Bayer Schering Pharma and Titan Pharmaceuticals. STEPS trial – spheramine safety and efficacy study. National Library of Medicine, Bethesda, MD, USA (2000). NLM Identifier: NCT00206687 http://clinicaltrials.gov/show/ NCT00206687 (Accessed 25 June 2008)
- Stavanger University Hospital, King’s College London, Lund University Hospital. Efficacy and safety of memantine for Parkinson’s disease dementia (PDD) and dementia with Lewy bodies (DLB) (MEMPDD). National Library of Medicine, Bethesda, MD, USA (2000). NLM Identifier: NCT00630500 http://clinicaltrials.gov/show/ NCT00630500 (Accessed 27 June 2008)
- Memorial Hospital of Rhode Island, Ortho-McNeil Neurologics, Inc. Galantamine executive function in Parkinson’s disease. National Library of Medicine, Bethesda, MD, USA (2000). NLM Identifier: NCT00211588 http://clinicaltrials.gov/show/ NCT00211588 (Accessed 27 June 2008)
- Johns Hopkins University, Eli Lilly and Company. Treatment of executive dysfunction in Parkinson’s disease. National Library of Medicine, Bethesda, MD, USA (2000). NLM Identifier: NCT00286949 http://clinicaltrials.gov/show/ NCT00286949 (Accessed 27 June 2008)
- ACADIA Pharmaceuticals Inc. A study of safety and efficacy of pimavanserin (ACP-103) in patients with Parkinson’s disease psychosis. National Library of Medicine, Bethesda, MD, USA (2000). NLM Identifiers: NCT00658567, NCT00477672, NCT00550238 http://clinicaltrials.gov/show/ NCT00658567 (Accessed 27 June 2008)
- University of Rochester, National Institute of Neurological Disorders and Stroke (NINDS). Study of antidepressants in Parkinson’s disease (SAD-PD). National Library of Medicine, Bethesda, MD, USA (2000). NLM Identifier: NCT00086190 http://clinicaltrials.gov/show/ NCT00086190 (Accessed 27 June 2008)
- Eli Lilly and Company. Study on the tolerability of duloxetine in depressed patients with Parkinson’s disease. National Library of Medicine, Bethesda, MD, USA (2000). NLM Identifier: NCT00437125 http://clinicaltrials.gov/show/ NCT00437125 (Accessed 27 June 2008)
- Baylor College of Medicine, National Parkinson Foundation. Acamprosate for treatment of compulsive behaviors and craving in Parkinson’s disease. National Library of Medicine, Bethesda, MD, USA (2000). NLM Identifier: NCT00640952 http://clinicaltrials.gov/show/ NCT00640952 (Accessed 27 June 2008)
- Waknine Y. New FDA orphan drugs: droxidopa, LX201, marqibo. Medscape Medical News. 30 January (2007) www.medscape.com/viewarticle/551478 (Accessed June 27 2008)
- Chelsea Therapeutics, Chiltern. Clinical study of droxidopa in patients with neurogenic orthostatic hypotension (NOH). National Library of Medicine, Bethesda, MD, USA (2000). NLM Identifier: NCT00633880 http://clinicaltrials.gov/show/ NCT00633880 (Accessed 27 June 2008)